酪氨酸激酶抑制剂治疗慢性髓系白血病疗效预测的研究进展

Progress of Researches on Prediction of Tyrosine Kinase Inhibitor Efficacy for Treatment of Chronic Myelocid Leukemia——Review

酪氨酸激酶抑制剂(TKI)已使慢性髓系白血病的临床疗效有了突破性的提高,但TKI耐药和患者不耐受的出现使部分患者难以获得满意疗效,治疗前筛选出高危患者以选用合适的TKI以及在治疗过程中早期发现耐药而及时转换TKI,有助于TKI的精准使用和疗效的进一步提高。本文就初诊患者基线临床、生化和分子生物学特征和伊马替尼早期治疗反应规律对患者远期预后影响的最新研究进展作一综述。

Tyrosine kinase inhibitors（TKI） have made a dramatic improvement in the clinical efficacy of chronic myelogenous leukemia,but the occurrence of TKL resistance and intolerance does not enable some patients to acquire the satisfactory efficacy.Screening the proper TKL for patients with high risk before the treatment and conversing drug timely based on early detection of TKL resistance are helpful to accurately use TKI and enhance therapeutic efficacy.In this article,the function of some indicators,such as baseline clinical,biochemical and molecular biological characteristics and influence of early treatment response law of imatinib on long-term prognosis of newly diagnosed patients are summarized.